Effects of c-mpl ligand on cytoplasmic maturation of murine megakaryocytes and on platelet production.
To test the hypothesis that the c-mpl ligand is not a primary factor in thrombocytopoiesis, we investigated the biological effects of recombinant human (rh) c-mpl ligand on differentiation of murine progenitor cells and on maturation of the cultured murine megakaryocytes under serum-free conditions on the basis of ploidy distribution, megakaryocyte/platelet-specific surface antigen CD 61 [glycoprotein (GP) IIIa], and cytoplasmic acetylcholinesterase (AchE) expression in vitro. In addition, we studied the effect of c-mpl ligand on proplatelet formation (PPF) by murine mature megakaryocytes. AchE was less strongly expressed in cultured megakaryocytic cells stimulated by c-mpl ligand than in those stimulated by recombinant murine (rm) IL-3 + rh IL-6 during the differentiation of progenitor cells. Less CD 61 was expressed by c-mpl ligand during both the differentiation of progenitor cells and the maturation of megakaryocytes compared with that by rm IL-3 + rh IL-6. Endomitosis, however, was more stimulated by c-mpl ligand than by rm IL-3 + rh IL-6 under both conditions. Furthermore, PPF of mature megakaryocytes was not stimulated by c-mpl ligand. These results indicate that c-mpl ligand stimulates the nuclear development of megakaryocytic cells but that it does not stimulate cytoplasmic maturation and PPF as much as IL-6. These data strongly suggest that c-mpl ligand is not a primary factor in platelet pro-duction. (J Histochem Cytochem 46:49-57, 1998)
Ishida
Y
Y
Iwate Medical University, School of Medicine, Division of Hematology, Morioka 020, Japan.
Ito
T
T
Kuriya
S i
Si
D000110:Acetylcholinesterase / Q000096:biosynthesis; D000818:Animals; D015703:Antigens, CD / Q000096:biosynthesis; D001792:Blood Platelets / Q000166:cytology* / Q000187:drug effects; D001854:Bone Marrow Cells / Q000166:cytology / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology*; D002478:Cells, Cultured; D003593:Cytoplasm / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D006801:Humans; D039661:Integrin beta3; D007377:Interleukin-3 / Q000494:pharmacology; D015850:Interleukin-6 / Q000494:pharmacology; D008533:Megakaryocytes / Q000166:cytology* / Q000187:drug effects; D051379:Mice; D010980:Platelet Membrane Glycoproteins / Q000096:biosynthesis; D011003:Ploidies; D011994:Recombinant Proteins / Q000494:pharmacology; D013926:Thrombopoietin / Q000378:metabolism* / Q000494:pharmacology
D015703:Antigens, CD; D039661:Integrin beta3; D007377:Interleukin-3; D015850:Interleukin-6; D010980:Platelet Membrane Glycoproteins; D011994:Recombinant Proteins; D013926:Thrombopoietin; D000110:Acetylcholinesterase